Login to Your Account



Financings Roundup

AGTC Cleans Up with $37.5M Series B; It's Good 'Eye Gene'

By Randy Osborne
Staff Writer

Tuesday, November 20, 2012
Riding the wave of success at last for gene therapy, privately held Applied Genetic Technologies Corp. (AGTC) bagged $37.5 million in a Series B financing that will let the company finish two Phase II trials with separate drug candidates, and see the firm through a pair of new, Phase I/II studies with other compounds in orphan eye diseases.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription